Objectives

Meningiomas are the most common primary intracranial tumor. Hepatocyte growth factor (HGF) and its receptor, cMet, were shown to be involved in meningioma. This study was aimed to determine the concentration of HGF and soluble cMet (s-cMet) in the serum of patients with different grades of meningioma.

Methods

Ninety serum samples from different grades of meningioma patients (42 cases of grade I, 28 grade II, 20 grade III) and 51 controls were included in this study. The serum total protein concentration (TPC) was measured by a Bio-Rad protein assay and serum concentration of HGF and s-cMet by enzyme linked immunosorbent assay (ELISA).

Results

No significant change in the serum TPC of patients was seen as compared to controls. We also showed that serum HGF and s-cMet concentration in meningioma patients was higher than in controls. The results showed that starting from grades I to III meningioma, a significant increase in HGF and s-cMet serum concentration was observed (HGF; 380 ± 57.69, 430.27 ± 48.72, 596.36 ± 104.49 pg/ml, respectively, as compared to controls which was 327.72 ± 49.68 pg/ml and for s-cMet was 274.45 ± 45.05, 314.81 ± 38.71, 433.54 ± 51.81 ng/ml, respectively, as compared to controls which was 213.72 ± 29.13 ng/ml). The results showed that a high concentration of HGF and s-cMet is associated with advanced grades of meningioma.

Conclusion

It is concluded that HGF and s-cMet serum levels increased in meningioma patients and their concentration was significantly higher in more advanced grades of the disease. It is also suggested that HGF/s-cMet might be involved in the progression of meningioma.

中文翻译：

---

不同级别脑膜瘤患者血清中肝细胞生长因子及其可溶性受体（s-cMet）的过表达

目标

脑膜瘤是最常见的原发性颅内肿瘤。肝细胞生长因子 (HGF) 及其受体 cMet 被证明与脑膜瘤有关。本研究旨在测定不同级别脑膜瘤患者血清中HGF和可溶性cMet（s-cMet）的浓度。

方法

本研究共收集了不同级别脑膜瘤患者的90份血清样本（I级42例，II级28例，III级20例）和51例对照。血清总蛋白浓度 (TPC) 通过 Bio-Rad 蛋白测定法测定，HGF 和 s-cMet 的血清浓度通过酶联免疫吸附测定法 (ELISA) 测定。

结果

与对照组相比，未观察到患者血清 TPC 的显着变化。我们还发现脑膜瘤患者的血清 HGF 和 s-cMet 浓度高于对照组。结果显示，从 I 级到 III 级脑膜瘤，观察到 HGF 和 s-cMet 血清浓度显着增加（HGF；分别为 380±57.69、430.27±48.72、596.36±104.49 pg/ml，与对照组相比，为 327.72 ± 49.68 pg/ml，s-cMet 分别为 274.45 ± 45.05、314.81 ± 38.71、433.54 ± 51.81 ng/ml，而对照为 213.72 ± 29 ng/ml）。结果表明，高浓度的 HGF 和 s-cMet 与高级脑膜瘤有关。

结论

得出的结论是，脑膜瘤患者的 HGF 和 s-cMet 血清水平升高，并且在疾病的更晚期，它们的浓度显着升高。还表明 HGF/s-cMet 可能参与脑膜瘤的进展。